Alx Oncology Holdings Inc.
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company developing therapies for cancer. Its pipeline includes evorpacept, a CD47-blocking fusion protein designed for use in combination with other anticancer agents, and ALX2004, an EGFR-targeted antibody-drug conjugate. Evorpacept is being studied in… From the company’s description.
In fiscal 2025, Alx Oncology Holdings Inc. reported a net loss of $101.69M. Operations used $84.14M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alx Oncology Holdings Inc. does
In the company’s own words
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company developing therapies for cancer. Its pipeline includes evorpacept, a CD47-blocking fusion protein designed for use in combination with other anticancer agents, and ALX2004, an EGFR-targeted antibody-drug conjugate. Evorpacept is being studied in clinical trials with targeted cancer antibodies and other treatments, including in HER2-positive breast cancer and other solid and blood cancers. ALX2004 entered a Phase 1 trial in 2025 for patients with advanced or metastatic EGFR-expressing solid tumors. The company’s development approach focuses on combining evorpacept with therapies that provide immune-stimulating signals, while its ADC research includes a proprietary linker-payload library. Evorpacept has been administered to approximately 800 subjects in combination studies. The company also works with pharmaceutical companies and academic medical centers on clinical trials of evorpacept with partners’ anticancer agents.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1810182
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alx Oncology Holdings Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alx Oncology Holdings Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alx Oncology Holdings Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alx Oncology Holdings Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alx Oncology Holdings Inc.'s last four quarterly filings that the numbers alone won't show?”